Co-Organised Event - London 08-09 March, 2019


Key deadlines

Abstract submissionis now closed



The purpose of this workshop is to bring together the academic, regulatory and pharmaceutical (diagnostic and therapeutic) communities to discuss therapeutic endpoints, trial designs, appropriate patient populations and safety concerns with regards to novel therapeutic approaches aimed to achieve HBV cure. This meeting will bring all the stakeholders together to discuss definitions of HBV cure, likelihood of HBV cure with currently approved therapies, preclinical and clinical data on novel antiviral and immune modulatory therapies, appropriate designs and endpoints for trials to evaluate therapies aimed at HBV and HDV cure, and strategies to efficiently and safely evaluate combination therapies. These discussions will provide guidance regarding potential pathways leading to regulatory approval of therapies that will result in high rates of HBV cure in individuals with chronic hepatitis B and chronic hepatitis D.


Who should attend?

  • Academic scientists
  • Clinical investigators
  • Physicians interested in the care of patients with hepatitis B
  • Regulatory agency staff
  • Diagnostic and therapeutic industry staff


Abstract submission is now closed

For anything you need to know about abstract submission process, dates and presenter guidelines, download the abstracts information document.

EASL has prepared an abstract submission checklist to guide you through your submission.




For anything you need to know about registration process, dates, registration fees and YI bursaries, download the registration information document.

Early fee registration deadline: 07 January 2019

On-site registration is also possible:

08 March 2019 from 07:00 to 19:00 & 09 March 2019 from 08:00 to 19:00




For anything you need to know about venue, your accommodation and booking process, download the get ready information document.

EASL has negociated special rates for conference delegates at the Novotel London Excel, however, the number of rooms to be booked is limited. We therefor recommend to book you accommodation early.


EASL welcomes the interest of the media in matters relating to hepatology and is happy to provide assistance to journalists who wish to attend the EASL-AASLD HBV Endpoints meeting held in London, United Kingdom.

Registered press representatives will have access to all sessions including the Exhibition.

Please contact EASL Press Office with any questions regarding media, press registration, audio or video recording.

HYATT Antognini Amin

Tel: +41 (0) 22 807 29 88
Fax: +41 (0) 22 328 07 24

Any questions?

Should you have any question about the event, your registration or accommodation, please contact



Supported by Janssen.

Janssen has had no input into the content of the materials and presentations used at this event.